Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis

Current studies have revealed that the platelet to lymphocyte ratio (PLR) may lead to a poor prognosis in lung cancer patients receiving immunotherapy. We conducted a meta-analysis to explore the prognostic value of PLR in lung cancer patients receiving immunotherapy. We retrieved potential studies...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 17; no. 5; p. e0268288
Main Authors Wang, Haoyu, Li, Cui, Yang, Ruiyuan, Jin, Jing, Liu, Dan, Li, Weimin
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 06.05.2022
Public Library of Science (PLoS)
Subjects
Bias
Biology and Life Sciences
Biomarkers
Cancer therapies
Complications and side effects
Confidence intervals
Ethnicity
Immunotherapy
Lung cancer
Lung diseases
Lymphocytes
Medical ethics
Medical prognosis
Medicine and Health Sciences
Meta-analysis
Patient outcomes
Patients
Physical Sciences
Platelets
Prognosis
Research and Analysis Methods
Sample size
Science Policy
Sensitivity analysis
Statistical analysis
Subgroups
Survival
Systematic review
China
Online AccessGet full text

Cover

Abstract Current studies have revealed that the platelet to lymphocyte ratio (PLR) may lead to a poor prognosis in lung cancer patients receiving immunotherapy. We conducted a meta-analysis to explore the prognostic value of PLR in lung cancer patients receiving immunotherapy. We retrieved potential studies from the PubMed, Web of Science, Embase, and Scopus databases up to June 2021 and merged the hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) to evaluate the association between PLR and overall survival (OS) or progression-free survival. Fourteen studies involving 1761 patients were included in our meta-analysis. The results indicated that an elevated level of pretreatment PLR was associated with poorer OS and PFS in lung cancer patients receiving immunotherapy (OS: HR = 1.88, 95% CI: 1.37-2.58; PFS: HR = HR = 1.40, 95% CI: 1.11-1.76). The association remained consistent after subgroup analysis and was robust even after sensitivity analysis. PLR may be a prognostic factor of lung cancer patients receiving immunotherapy, which can lead to worse survival outcomes. However, further studies are necessary for evidence in clinical application.
AbstractList Current studies have revealed that the platelet to lymphocyte ratio (PLR) may lead to a poor prognosis in lung cancer patients receiving immunotherapy. We conducted a meta-analysis to explore the prognostic value of PLR in lung cancer patients receiving immunotherapy.BACKGROUNDCurrent studies have revealed that the platelet to lymphocyte ratio (PLR) may lead to a poor prognosis in lung cancer patients receiving immunotherapy. We conducted a meta-analysis to explore the prognostic value of PLR in lung cancer patients receiving immunotherapy.We retrieved potential studies from the PubMed, Web of Science, Embase, and Scopus databases up to June 2021 and merged the hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) to evaluate the association between PLR and overall survival (OS) or progression-free survival.METHODSWe retrieved potential studies from the PubMed, Web of Science, Embase, and Scopus databases up to June 2021 and merged the hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) to evaluate the association between PLR and overall survival (OS) or progression-free survival.Fourteen studies involving 1761 patients were included in our meta-analysis. The results indicated that an elevated level of pretreatment PLR was associated with poorer OS and PFS in lung cancer patients receiving immunotherapy (OS: HR = 1.88, 95% CI: 1.37-2.58; PFS: HR = HR = 1.40, 95% CI: 1.11-1.76). The association remained consistent after subgroup analysis and was robust even after sensitivity analysis.RESULTSFourteen studies involving 1761 patients were included in our meta-analysis. The results indicated that an elevated level of pretreatment PLR was associated with poorer OS and PFS in lung cancer patients receiving immunotherapy (OS: HR = 1.88, 95% CI: 1.37-2.58; PFS: HR = HR = 1.40, 95% CI: 1.11-1.76). The association remained consistent after subgroup analysis and was robust even after sensitivity analysis.PLR may be a prognostic factor of lung cancer patients receiving immunotherapy, which can lead to worse survival outcomes. However, further studies are necessary for evidence in clinical application.CONCLUSIONSPLR may be a prognostic factor of lung cancer patients receiving immunotherapy, which can lead to worse survival outcomes. However, further studies are necessary for evidence in clinical application.
Background Current studies have revealed that the platelet to lymphocyte ratio (PLR) may lead to a poor prognosis in lung cancer patients receiving immunotherapy. We conducted a meta-analysis to explore the prognostic value of PLR in lung cancer patients receiving immunotherapy. Methods We retrieved potential studies from the PubMed, Web of Science, Embase, and Scopus databases up to June 2021 and merged the hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) to evaluate the association between PLR and overall survival (OS) or progression-free survival. Results Fourteen studies involving 1761 patients were included in our meta-analysis. The results indicated that an elevated level of pretreatment PLR was associated with poorer OS and PFS in lung cancer patients receiving immunotherapy (OS: HR = 1.88, 95% CI: 1.37–2.58; PFS: HR = HR = 1.40, 95% CI: 1.11–1.76). The association remained consistent after subgroup analysis and was robust even after sensitivity analysis. Conclusions PLR may be a prognostic factor of lung cancer patients receiving immunotherapy, which can lead to worse survival outcomes. However, further studies are necessary for evidence in clinical application.
Current studies have revealed that the platelet to lymphocyte ratio (PLR) may lead to a poor prognosis in lung cancer patients receiving immunotherapy. We conducted a meta-analysis to explore the prognostic value of PLR in lung cancer patients receiving immunotherapy. We retrieved potential studies from the PubMed, Web of Science, Embase, and Scopus databases up to June 2021 and merged the hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) to evaluate the association between PLR and overall survival (OS) or progression-free survival. Fourteen studies involving 1761 patients were included in our meta-analysis. The results indicated that an elevated level of pretreatment PLR was associated with poorer OS and PFS in lung cancer patients receiving immunotherapy (OS: HR = 1.88, 95% CI: 1.37-2.58; PFS: HR = HR = 1.40, 95% CI: 1.11-1.76). The association remained consistent after subgroup analysis and was robust even after sensitivity analysis. PLR may be a prognostic factor of lung cancer patients receiving immunotherapy, which can lead to worse survival outcomes. However, further studies are necessary for evidence in clinical application.
BackgroundCurrent studies have revealed that the platelet to lymphocyte ratio (PLR) may lead to a poor prognosis in lung cancer patients receiving immunotherapy. We conducted a meta-analysis to explore the prognostic value of PLR in lung cancer patients receiving immunotherapy.MethodsWe retrieved potential studies from the PubMed, Web of Science, Embase, and Scopus databases up to June 2021 and merged the hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) to evaluate the association between PLR and overall survival (OS) or progression-free survival.ResultsFourteen studies involving 1761 patients were included in our meta-analysis. The results indicated that an elevated level of pretreatment PLR was associated with poorer OS and PFS in lung cancer patients receiving immunotherapy (OS: HR = 1.88, 95% CI: 1.37-2.58; PFS: HR = HR = 1.40, 95% CI: 1.11-1.76). The association remained consistent after subgroup analysis and was robust even after sensitivity analysis.ConclusionsPLR may be a prognostic factor of lung cancer patients receiving immunotherapy, which can lead to worse survival outcomes. However, further studies are necessary for evidence in clinical application.
Current studies have revealed that the platelet to lymphocyte ratio (PLR) may lead to a poor prognosis in lung cancer patients receiving immunotherapy. We conducted a meta-analysis to explore the prognostic value of PLR in lung cancer patients receiving immunotherapy. We retrieved potential studies from the PubMed, Web of Science, Embase, and Scopus databases up to June 2021 and merged the hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) to evaluate the association between PLR and overall survival (OS) or progression-free survival. Fourteen studies involving 1761 patients were included in our meta-analysis. The results indicated that an elevated level of pretreatment PLR was associated with poorer OS and PFS in lung cancer patients receiving immunotherapy (OS: HR = 1.88, 95% CI: 1.37-2.58; PFS: HR = HR = 1.40, 95% CI: 1.11-1.76). The association remained consistent after subgroup analysis and was robust even after sensitivity analysis. PLR may be a prognostic factor of lung cancer patients receiving immunotherapy, which can lead to worse survival outcomes. However, further studies are necessary for evidence in clinical application.
Background Current studies have revealed that the platelet to lymphocyte ratio (PLR) may lead to a poor prognosis in lung cancer patients receiving immunotherapy. We conducted a meta-analysis to explore the prognostic value of PLR in lung cancer patients receiving immunotherapy. Methods We retrieved potential studies from the PubMed, Web of Science, Embase, and Scopus databases up to June 2021 and merged the hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) to evaluate the association between PLR and overall survival (OS) or progression-free survival. Results Fourteen studies involving 1761 patients were included in our meta-analysis. The results indicated that an elevated level of pretreatment PLR was associated with poorer OS and PFS in lung cancer patients receiving immunotherapy (OS: HR = 1.88, 95% CI: 1.37-2.58; PFS: HR = HR = 1.40, 95% CI: 1.11-1.76). The association remained consistent after subgroup analysis and was robust even after sensitivity analysis. Conclusions PLR may be a prognostic factor of lung cancer patients receiving immunotherapy, which can lead to worse survival outcomes. However, further studies are necessary for evidence in clinical application.
Audience Academic
Author Li, Weimin
Wang, Haoyu
Li, Cui
Yang, Ruiyuan
Jin, Jing
Liu, Dan
AuthorAffiliation 1 Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
Shuguang Hospital, CHINA
2 Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China
AuthorAffiliation_xml – name: 1 Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
– name: Shuguang Hospital, CHINA
– name: 2 Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China
Author_xml – sequence: 1
  givenname: Haoyu
  surname: Wang
  fullname: Wang, Haoyu
– sequence: 2
  givenname: Cui
  surname: Li
  fullname: Li, Cui
– sequence: 3
  givenname: Ruiyuan
  surname: Yang
  fullname: Yang, Ruiyuan
– sequence: 4
  givenname: Jing
  surname: Jin
  fullname: Jin, Jing
– sequence: 5
  givenname: Dan
  surname: Liu
  fullname: Liu, Dan
– sequence: 6
  givenname: Weimin
  orcidid: 0000-0001-8622-4336
  surname: Li
  fullname: Li, Weimin
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35522679$$D View this record in MEDLINE/PubMed
BookMark eNqNk9tq3DAQhk1JaQ7tG5RWUCjthbeSLUt2Lgoh9LAQSOnpVmjl8a6CLLmSvO0-Q1-6crMJuyGU4gub0Tf_aH7PHGcH1lnIsqcEz0jJyZsrN3orzWxI4RkuWF3U9YPsiDRlkbMClwc734fZcQhXGFdlzdij7LCsqqJgvDnKfn_ybmldiFqhtTQjINehuAI0GBnBQMyjy82mH1ZObSIgL6N2SFtkRrtESloFHg0pCDYG5EGBXut0ovt-tC4JeTlsTtEZCpsQoZdTHQ9rDT-RtC3qIcpcpjY2QYfH2cNOmgBPtu-T7Nv7d1_PP-YXlx_m52cXuWJNEfO2w7QlLesaruqmAyqlLBeU0ZJgzNtFRaquoEWXGm8rYHzR0AYrQhooC4rLujzJnl_rDsYFsfUxiGRhSmkwnYj5NdE6eSUGr3vpN8JJLf4GnF8K6VMrBgRpO1LIhSzbdJO6YjXUipOSglIKA-2S1ttttXHRQ6uSUV6aPdH9E6tXYunWosG8YhVOAq-2At79GCFE0eugwBhpwY3TvRnBnHFOE_riDnp_d1tqKVMD2nYu1VWTqDjjuOAFx5QnanYPlZ4Weq3S0HU6xfcSXu8lJCbCr7iUYwhi_uXz_7OX3_fZlzvsCqSJq-DMmAbRhn3w2a7TtxbfTHsC6DWgvAvBQ3eLECympbqxS0xLJbZLldJO76QpHac9mP6XNv9O_gOv6ip3
CitedBy_id crossref_primary_10_1016_j_canlet_2024_217044
crossref_primary_10_3389_fonc_2023_1141500
crossref_primary_10_1016_j_ctarc_2023_100752
crossref_primary_10_3390_pharmaceutics14102029
crossref_primary_10_1016_j_critrevonc_2024_104525
crossref_primary_10_3389_fonc_2023_1253895
crossref_primary_10_1177_1721727X231197494
crossref_primary_10_3390_medicina58101397
crossref_primary_10_1038_s41598_024_84343_x
crossref_primary_10_3390_jcm12062409
crossref_primary_10_36401_JIPO_23_3
Cites_doi 10.1146/annurev.immunol.26.021607.090331
10.1016/S1470-2045(14)70263-3
10.21037/jtd.2020.02.27
10.2147/OTT.S96804
10.21037/tlcr.2019.11.16
10.1097/JTO.0b013e318244ffe1
10.1371/journal.pone.0219060
10.1038/nrc3611
10.1056/NEJMc1713444
10.1093/annonc/mdy495
10.1136/bmj.k793
10.1371/journal.pmed.1000100
10.1016/j.jtho.2020.03.006
10.1016/S1470-2045(15)00307-1
10.1056/NEJMoa1801946
10.1038/nature21706
10.1016/j.lungcan.2020.12.027
10.1056/NEJMoa1510665
10.1016/j.lungcan.2020.04.034
10.21037/tlcr-20-541
10.1016/j.intimp.2020.106677
10.1038/s41598-020-74573-0
10.1007/s00262-017-2092-x
10.1200/JCO.2016.67.9761
10.1200/JCO.2014.59.4358
10.1146/annurev-pathol-042020-042741
10.1158/1078-0432.CCR-15-1678
10.1093/annonc/mdv489
10.1158/0008-5472.CAN-18-0887
10.1016/S1470-2045(18)30261-4
10.1016/S0140-6736(15)01281-7
10.21873/anticanres.13048
10.1038/srep22618
10.1186/1745-6215-8-16
10.1097/MCP.0b013e328209413c
10.1111/1759-7714.12838
10.1056/NEJMoa1504627
10.7150/thno.64252
10.1002/jcla.22964
10.1056/NEJMoa1507643
10.1056/NEJMoa0810699
10.3389/fonc.2020.00913
10.1016/S1470-2045(20)30328-4
10.1007/s12325-020-01229-w
10.1182/blood-2018-12-852830
10.1016/j.intimp.2019.105957
10.1371/journal.pone.0184412
10.1016/j.lungcan.2017.07.024
10.1634/theoncologist.2018-0563
ContentType Journal Article
Copyright COPYRIGHT 2022 Public Library of Science
2022 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022 Wang et al 2022 Wang et al
Copyright_xml – notice: COPYRIGHT 2022 Public Library of Science
– notice: 2022 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022 Wang et al 2022 Wang et al
DBID AAYXX
CITATION
NPM
IOV
ISR
3V.
7QG
7QL
7QO
7RV
7SN
7SS
7T5
7TG
7TM
7U9
7X2
7X7
7XB
88E
8AO
8C1
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABJCF
ABUWG
AEUYN
AFKRA
ARAPS
ATCPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
KB.
KB0
KL.
L6V
LK8
M0K
M0S
M1P
M7N
M7P
M7S
NAPCQ
P5Z
P62
P64
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PTHSS
PYCSY
RC3
7X8
5PM
DOA
DOI 10.1371/journal.pone.0268288
DatabaseName CrossRef
PubMed
Gale In Context: Opposing Viewpoints
Gale In Context: Science
ProQuest Central (Corporate)
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Nursing & Allied Health Database
Ecology Abstracts
Entomology Abstracts (Full archive)
Immunology Abstracts
Meteorological & Geoastrophysical Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Agricultural Science Collection
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Advanced Technologies & Aerospace Collection
Agricultural & Environmental Science Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One
ProQuest Materials Science Collection
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Materials Science Database
Nursing & Allied Health Database (Alumni Edition)
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest Engineering Collection
Biological Sciences
Agricultural Science Database
Health & Medical Collection (Alumni)
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Engineering Database
Nursing & Allied Health Premium
ProQuest advanced technologies & aerospace journals
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
Environmental Science Database
Materials Science Collection
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
Engineering Collection
Environmental Science Collection
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Agricultural Science Database
Publicly Available Content Database
ProQuest Central Student
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Meteorological & Geoastrophysical Abstracts
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Engineering Collection
Advanced Technologies & Aerospace Collection
Engineering Database
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Agricultural Science Collection
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Science Collection
Entomology Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
ProQuest Engineering Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Agricultural & Environmental Science Collection
AIDS and Cancer Research Abstracts
Materials Science Database
ProQuest Materials Science Collection
ProQuest Public Health
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Animal Behavior Abstracts
Materials Science & Engineering Collection
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic





PubMed

Agricultural Science Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
DocumentTitleAlternate Platelet-to-lymphocyte ratio and the prognosis of lung cancer
EISSN 1932-6203
ExternalDocumentID 2686209048
oai_doaj_org_article_1df12aba3dfe48568e8c7134eccc0e4f
PMC9075650
A702727047
35522679
10_1371_journal_pone_0268288
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: ;
  grantid: 81871890
– fundername: ;
  grantid: 2020-YF08-00080-GX
– fundername: ;
  grantid: 91859203
GroupedDBID ---
123
29O
2WC
53G
5VS
7RV
7X2
7X7
7XC
88E
8AO
8C1
8CJ
8FE
8FG
8FH
8FI
8FJ
A8Z
AAFWJ
AAUCC
AAWOE
AAYXX
ABDBF
ABIVO
ABJCF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
APEBS
ARAPS
ATCPS
BAWUL
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BKEYQ
BPHCQ
BVXVI
BWKFM
CCPQU
CITATION
CS3
D1I
D1J
D1K
DIK
DU5
E3Z
EAP
EAS
EBD
EMOBN
ESX
EX3
F5P
FPL
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
IAO
IEA
IGS
IHR
IHW
INH
INR
IOV
IPY
ISE
ISR
ITC
K6-
KB.
KQ8
L6V
LK5
LK8
M0K
M1P
M48
M7P
M7R
M7S
M~E
NAPCQ
O5R
O5S
OK1
OVT
P2P
P62
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PTHSS
PV9
PYCSY
RNS
RPM
RZL
SV3
TR2
UKHRP
WOQ
WOW
~02
~KM
ADRAZ
IPNFZ
NPM
PJZUB
PPXIY
PQGLB
RIG
BBORY
PMFND
3V.
7QG
7QL
7QO
7SN
7SS
7T5
7TG
7TM
7U9
7XB
8FD
8FK
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
KL.
M7N
P64
PKEHL
PQEST
PQUKI
RC3
7X8
5PM
PUEGO
AAPBV
ABPTK
BBAFP
N95
ID FETCH-LOGICAL-c692t-df04d1d6f97c89fe4aaa3b46431007db515f242f620d5e67b9490c119e3240383
IEDL.DBID M48
ISSN 1932-6203
IngestDate Sun Nov 06 00:11:09 EDT 2022
Wed Aug 27 01:31:54 EDT 2025
Thu Aug 21 13:42:42 EDT 2025
Mon Jul 21 10:31:56 EDT 2025
Fri Jul 25 11:14:29 EDT 2025
Tue Jun 17 20:57:23 EDT 2025
Tue Jun 10 20:27:04 EDT 2025
Fri Jun 27 03:39:32 EDT 2025
Fri Jun 27 04:38:10 EDT 2025
Thu May 22 20:54:13 EDT 2025
Mon Jul 21 06:00:20 EDT 2025
Tue Jul 01 01:41:40 EDT 2025
Thu Apr 24 23:00:44 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Creative Commons Attribution License
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c692t-df04d1d6f97c89fe4aaa3b46431007db515f242f620d5e67b9490c119e3240383
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Competing Interests: The authors have declared that no competing interests exist.
ORCID 0000-0001-8622-4336
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0268288
PMID 35522679
PQID 2686209048
PQPubID 1436336
PageCount e0268288
ParticipantIDs plos_journals_2686209048
doaj_primary_oai_doaj_org_article_1df12aba3dfe48568e8c7134eccc0e4f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9075650
proquest_miscellaneous_2661076774
proquest_journals_2686209048
gale_infotracmisc_A702727047
gale_infotracacademiconefile_A702727047
gale_incontextgauss_ISR_A702727047
gale_incontextgauss_IOV_A702727047
gale_healthsolutions_A702727047
pubmed_primary_35522679
crossref_primary_10_1371_journal_pone_0268288
crossref_citationtrail_10_1371_journal_pone_0268288
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20220506
PublicationDateYYYYMMDD 2022-05-06
PublicationDate_xml – month: 5
  year: 2022
  text: 20220506
  day: 6
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: San Francisco
– name: San Francisco, CA USA
PublicationTitle PloS one
PublicationTitleAlternate PLoS One
PublicationYear 2022
Publisher Public Library of Science
Public Library of Science (PLoS)
Publisher_xml – name: Public Library of Science
– name: Public Library of Science (PLoS)
References S Bagchi (pone.0268288.ref007) 2021; 16
M Yarchoan (pone.0268288.ref013) 2017; 377
H Zhang (pone.0268288.ref044) 2016; 6
E Lefrançais (pone.0268288.ref046) 2017; 544
T Matsubara (pone.0268288.ref029) 2020; 12
MD Hellmann (pone.0268288.ref015) 2018; 378
S Diem (pone.0268288.ref022) 2017; 111
M Ilie (pone.0268288.ref012) 2016; 27
EY Leung (pone.0268288.ref017) 2012; 7
CI Diakos (pone.0268288.ref042) 2014; 15
Y Katayama (pone.0268288.ref025) 2020; 10
H Xu (pone.0268288.ref051) 2019; 77
J Brahmer (pone.0268288.ref036) 2015; 373
RJ Motzer (pone.0268288.ref041) 2015; 373
D Ksienski (pone.0268288.ref026) 2021; 10
JF Tierney (pone.0268288.ref021) 2007; 8
A Russo (pone.0268288.ref031) 2020; 37
J Liu (pone.0268288.ref027) 2019; 33
A Liberati (pone.0268288.ref019) 2009; 6
ME Tesselaar (pone.0268288.ref047) 2007; 13
RS Herbst (pone.0268288.ref004) 2016; 387
H Sung (pone.0268288.ref001) 2021; 71
J Jin (pone.0268288.ref016) 2017; 12
T Takeda (pone.0268288.ref035) 2018; 9
C Massard (pone.0268288.ref037) 2016; 34
M Svaton (pone.0268288.ref033) 2018; 38
E Elinav (pone.0268288.ref043) 2013; 13
MA Postow (pone.0268288.ref006) 2015; 33
N Zhang (pone.0268288.ref052) 2020; 85
H Borghaei (pone.0268288.ref014) 2015; 373
ME Keir (pone.0268288.ref005) 2008; 26
H Mandaliya (pone.0268288.ref018) 2019; 8
A Rodriguez-Martinez (pone.0268288.ref048) 2022; 12
G Qiang (pone.0268288.ref045) 2016; 9
JC Dudley (pone.0268288.ref040) 2016; 22
MG Best (pone.0268288.ref050) 2018; 78
TS Mok (pone.0268288.ref003) 2009; 361
M Dusselier (pone.0268288.ref023) 2019; 14
R Lobefaro (pone.0268288.ref028) 2021; 152
GA Wells BS DOC (pone.0268288.ref020) 2013
K Takada (pone.0268288.ref034) 2020; 145
RL Siegel (pone.0268288.ref002) 2021; 71
S Billan (pone.0268288.ref010) 2020; 21
A Fusi (pone.0268288.ref038) 2015; 16
S Baxi (pone.0268288.ref009) 2018; 360
F Conforti (pone.0268288.ref008) 2018; 19
M Jiang (pone.0268288.ref024) 2020; 10
J Remon (pone.0268288.ref011) 2020; 15
A Pavan (pone.0268288.ref030) 2019; 24
KJ Suh (pone.0268288.ref032) 2018; 67
TA Chan (pone.0268288.ref039) 2019; 30
S In ’t Veld (pone.0268288.ref049) 2019; 133
References_xml – volume: 26
  start-page: 677
  year: 2008
  ident: pone.0268288.ref005
  article-title: PD-1 and its ligands in tolerance and immunity
  publication-title: Annual review of immunology
  doi: 10.1146/annurev.immunol.26.021607.090331
– volume: 15
  start-page: e493
  issue: 11
  year: 2014
  ident: pone.0268288.ref042
  article-title: Cancer-related inflammation and treatment effectiveness
  publication-title: The Lancet Oncology
  doi: 10.1016/S1470-2045(14)70263-3
– volume: 12
  start-page: 1520
  issue: 4
  year: 2020
  ident: pone.0268288.ref029
  article-title: The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab
  publication-title: J Thorac Dis
  doi: 10.21037/jtd.2020.02.27
– volume: 9
  start-page: 869
  year: 2016
  ident: pone.0268288.ref045
  article-title: Prognostic significance of platelet-to-lymphocyte ratio in non-small-cell lung cancer: a meta-analysis.
  publication-title: OncoTargets and therapy
  doi: 10.2147/OTT.S96804
– volume: 8
  start-page: 886
  issue: 6
  year: 2019
  ident: pone.0268288.ref018
  article-title: Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI).
  publication-title: II.Translational lung cancer research.
  doi: 10.21037/tlcr.2019.11.16
– volume: 7
  start-page: 655
  issue: 4
  year: 2012
  ident: pone.0268288.ref017
  article-title: Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer
  publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer
  doi: 10.1097/JTO.0b013e318244ffe1
– volume: 14
  start-page: e0219060
  issue: 7
  year: 2019
  ident: pone.0268288.ref023
  article-title: Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers
  publication-title: PloS one
  doi: 10.1371/journal.pone.0219060
– volume: 13
  start-page: 759
  issue: 11
  year: 2013
  ident: pone.0268288.ref043
  article-title: Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms.
  publication-title: Nature reviews Cancer.
  doi: 10.1038/nrc3611
– volume: 377
  start-page: 2500
  issue: 25
  year: 2017
  ident: pone.0268288.ref013
  article-title: Tumor Mutational Burden and Response Rate to PD-1 Inhibition
  publication-title: The New England journal of medicine
  doi: 10.1056/NEJMc1713444
– volume: 30
  start-page: 44
  issue: 1
  year: 2019
  ident: pone.0268288.ref039
  article-title: Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
  publication-title: Annals of oncology: official journal of the European Society for Medical Oncology
  doi: 10.1093/annonc/mdy495
– volume: 360
  start-page: k793
  year: 2018
  ident: pone.0268288.ref009
  article-title: Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
  publication-title: BMJ (Clinical research ed).
  doi: 10.1136/bmj.k793
– volume: 6
  start-page: e1000100
  issue: 7
  year: 2009
  ident: pone.0268288.ref019
  article-title: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
  publication-title: PLoS medicine.
  doi: 10.1371/journal.pmed.1000100
– volume: 15
  start-page: 914
  issue: 6
  year: 2020
  ident: pone.0268288.ref011
  article-title: Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
  publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer
  doi: 10.1016/j.jtho.2020.03.006
– volume: 16
  start-page: 1285
  issue: 13
  year: 2015
  ident: pone.0268288.ref038
  article-title: PD-L1 expression as a potential predictive biomarker
  publication-title: The Lancet Oncology
  doi: 10.1016/S1470-2045(15)00307-1
– volume: 378
  start-page: 2093
  issue: 22
  year: 2018
  ident: pone.0268288.ref015
  article-title: Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
  publication-title: The New England journal of medicine
  doi: 10.1056/NEJMoa1801946
– year: 2013
  ident: pone.0268288.ref020
  article-title: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
– volume: 544
  start-page: 105
  issue: 7648
  year: 2017
  ident: pone.0268288.ref046
  article-title: The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors
  publication-title: Nature
  doi: 10.1038/nature21706
– volume: 71
  start-page: 7
  issue: 1
  year: 2021
  ident: pone.0268288.ref002
  article-title: Cancer Statistics, 2021.
  publication-title: CA: a cancer journal for clinicians.
– volume: 152
  start-page: 165
  year: 2021
  ident: pone.0268288.ref028
  article-title: Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2020.12.027
– volume: 373
  start-page: 1803
  issue: 19
  year: 2015
  ident: pone.0268288.ref041
  article-title: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
  publication-title: The New England journal of medicine
  doi: 10.1056/NEJMoa1510665
– volume: 145
  start-page: 18
  year: 2020
  ident: pone.0268288.ref034
  article-title: Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2020.04.034
– volume: 10
  start-page: 355
  issue: 1
  year: 2021
  ident: pone.0268288.ref026
  article-title: Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab.
  publication-title: Translational lung cancer research.
  doi: 10.21037/tlcr-20-541
– volume: 85
  start-page: 106677
  year: 2020
  ident: pone.0268288.ref052
  article-title: Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2020.106677
– volume: 10
  start-page: 17495
  issue: 1
  year: 2020
  ident: pone.0268288.ref025
  article-title: Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients
  publication-title: Sci Rep
  doi: 10.1038/s41598-020-74573-0
– volume: 67
  start-page: 459
  issue: 3
  year: 2018
  ident: pone.0268288.ref032
  article-title: Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-017-2092-x
– volume: 34
  start-page: 3119
  issue: 26
  year: 2016
  ident: pone.0268288.ref037
  article-title: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology.
  doi: 10.1200/JCO.2016.67.9761
– volume: 33
  start-page: 1974
  issue: 17
  year: 2015
  ident: pone.0268288.ref006
  article-title: Immune Checkpoint Blockade in Cancer Therapy.
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2014.59.4358
– volume: 16
  start-page: 223
  year: 2021
  ident: pone.0268288.ref007
  article-title: Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
  publication-title: Annual review of pathology
  doi: 10.1146/annurev-pathol-042020-042741
– volume: 22
  start-page: 813
  issue: 4
  year: 2016
  ident: pone.0268288.ref040
  article-title: Microsatellite Instability as a Biomarker for PD-1 Blockade.
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research.
  doi: 10.1158/1078-0432.CCR-15-1678
– volume: 27
  start-page: 147
  issue: 1
  year: 2016
  ident: pone.0268288.ref012
  article-title: Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
  publication-title: Annals of oncology: official journal of the European Society for Medical Oncology
  doi: 10.1093/annonc/mdv489
– volume: 78
  start-page: 3407
  issue: 13
  year: 2018
  ident: pone.0268288.ref050
  article-title: Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring
  publication-title: Cancer research
  doi: 10.1158/0008-5472.CAN-18-0887
– volume: 19
  start-page: 737
  issue: 6
  year: 2018
  ident: pone.0268288.ref008
  article-title: Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis
  publication-title: The Lancet Oncology
  doi: 10.1016/S1470-2045(18)30261-4
– volume: 387
  start-page: 1540
  issue: 10027
  year: 2016
  ident: pone.0268288.ref004
  article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
  publication-title: Lancet (London, England).
  doi: 10.1016/S0140-6736(15)01281-7
– volume: 38
  start-page: 6771
  issue: 12
  year: 2018
  ident: pone.0268288.ref033
  article-title: Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer
  publication-title: Anticancer Res
  doi: 10.21873/anticanres.13048
– volume: 6
  start-page: 22618
  year: 2016
  ident: pone.0268288.ref044
  article-title: Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis
  publication-title: Sci Rep
  doi: 10.1038/srep22618
– volume: 8
  start-page: 16
  year: 2007
  ident: pone.0268288.ref021
  article-title: Practical methods for incorporating summary time-to-event data into meta-analysis.
  publication-title: Trials
  doi: 10.1186/1745-6215-8-16
– volume: 13
  start-page: 362
  issue: 5
  year: 2007
  ident: pone.0268288.ref047
  article-title: Risk of venous thromboembolism in lung cancer
  publication-title: Current opinion in pulmonary medicine
  doi: 10.1097/MCP.0b013e328209413c
– volume: 9
  start-page: 1291
  issue: 10
  year: 2018
  ident: pone.0268288.ref035
  article-title: Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer
  publication-title: Thorac Cancer
  doi: 10.1111/1759-7714.12838
– volume: 373
  start-page: 123
  issue: 2
  year: 2015
  ident: pone.0268288.ref036
  article-title: Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
  publication-title: The New England journal of medicine
  doi: 10.1056/NEJMoa1504627
– volume: 12
  start-page: 2150
  issue: 5
  year: 2022
  ident: pone.0268288.ref048
  article-title: Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior.
  publication-title: Theranostics
  doi: 10.7150/thno.64252
– volume: 33
  start-page: e22964
  issue: 8
  year: 2019
  ident: pone.0268288.ref027
  article-title: Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab
  publication-title: J Clin Lab Anal
  doi: 10.1002/jcla.22964
– volume: 373
  start-page: 1627
  issue: 17
  year: 2015
  ident: pone.0268288.ref014
  article-title: Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
  publication-title: The New England journal of medicine
  doi: 10.1056/NEJMoa1507643
– volume: 361
  start-page: 947
  issue: 10
  year: 2009
  ident: pone.0268288.ref003
  article-title: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
  publication-title: The New England journal of medicine
  doi: 10.1056/NEJMoa0810699
– volume: 10
  start-page: 913
  year: 2020
  ident: pone.0268288.ref024
  article-title: Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy.
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.00913
– volume: 21
  start-page: e463
  issue: 10
  year: 2020
  ident: pone.0268288.ref010
  article-title: Treatment after progression in the era of immunotherapy
  publication-title: The Lancet Oncology
  doi: 10.1016/S1470-2045(20)30328-4
– volume: 37
  start-page: 1145
  issue: 3
  year: 2020
  ident: pone.0268288.ref031
  article-title: Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
  publication-title: Adv Ther.
  doi: 10.1007/s12325-020-01229-w
– volume: 133
  start-page: 2359
  issue: 22
  year: 2019
  ident: pone.0268288.ref049
  article-title: Tumor-educated platelets.
  publication-title: Blood
  doi: 10.1182/blood-2018-12-852830
– volume: 77
  start-page: 105957
  year: 2019
  ident: pone.0268288.ref051
  article-title: Evaluation of the prognostic role of platelet-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2019.105957
– volume: 12
  start-page: e0184412
  issue: 9
  year: 2017
  ident: pone.0268288.ref016
  article-title: Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis
  publication-title: PloS one
  doi: 10.1371/journal.pone.0184412
– volume: 111
  start-page: 176
  year: 2017
  ident: pone.0268288.ref022
  article-title: Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2017.07.024
– volume: 24
  start-page: 1128
  issue: 8
  year: 2019
  ident: pone.0268288.ref030
  article-title: Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2018-0563
– volume: 71
  start-page: 209
  issue: 3
  year: 2021
  ident: pone.0268288.ref001
  article-title: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
  publication-title: CA: a cancer journal for clinicians.
SSID ssj0053866
Score 2.4555368
SecondaryResourceType review_article
Snippet Current studies have revealed that the platelet to lymphocyte ratio (PLR) may lead to a poor prognosis in lung cancer patients receiving immunotherapy. We...
Background Current studies have revealed that the platelet to lymphocyte ratio (PLR) may lead to a poor prognosis in lung cancer patients receiving...
BackgroundCurrent studies have revealed that the platelet to lymphocyte ratio (PLR) may lead to a poor prognosis in lung cancer patients receiving...
Background Current studies have revealed that the platelet to lymphocyte ratio (PLR) may lead to a poor prognosis in lung cancer patients receiving...
SourceID plos
doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e0268288
SubjectTerms Bias
Biology and Life Sciences
Biomarkers
Cancer therapies
Complications and side effects
Confidence intervals
Ethnicity
Immunotherapy
Lung cancer
Lung diseases
Lymphocytes
Medical ethics
Medical prognosis
Medicine and Health Sciences
Meta-analysis
Patient outcomes
Patients
Physical Sciences
Platelets
Prognosis
Research and Analysis Methods
Sample size
Science Policy
Sensitivity analysis
Statistical analysis
Subgroups
Survival
Systematic review
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggyquBUgxCAg5u4zzsmNuCqAoHQEBRb5HjB6y0JKtN9rC_oX-amcQbGlSpHLiuJ8nuzHjmm-zMZ0KeqwLSeOwrlgM4YFmVc1Ypo5hQqcm5UZBT-wbZj-L0LPtwnp9fOuoLe8IGeuBBccfcep7oSqfWu6zIReEKg_OP8GgTu8xj9IWctyumhhgMu1iIMCiXSn4c7HK0amp3BFUHlBnFJBH1fP1jVJ6tlk17FeT8u3PyUio6uU1uBQxJ58N33yM3XH2H7IVd2tKXgUr61V1y8XndYCcdCFKk9Xa08RQgH10tAWOCyVjXsOUWLNqYbedo7w50UdMlxABq0CPWNFCvthSCo1vgCwi6wKmSMLu1fU3n9A8hNB2GYaiuLf3lOs10oD25R85O3n17e8rC8QvMCJV0zPo4s9wKr6QpFGhfa51WGUAY7KywYNbcQ4L3Iolt7oSsVKZiw7lyPclfkd4nsxoUvk9okXLhU2XRX7JcF0XlRSV9YivjubYiIunOFqUJ3OR4RMay7P9wk1CjDKot0YJlsGBE2HjVauDmuEb-DZp5lEVm7f4D8Lcy-Ft5nb9F5Ak6STmMqY7xoZxLKPATGWcyIs96CWTXqLF954fetG35_tP3fxD6-mUi9CII-QbUYXQYmYDfhKxdE8mDiSTECDNZ3keX3mmlLRMcDIoVhG-4cufmVy8_HZfxptiSV7tmgzKAvKWA8iEiD4ZdMWoWQCzAeqkiIif7ZaL66Uq9-NmTmyvAsFA1PPwftnpEbiY4rYL9qeKAzLr1xj0GDNlVh324-A0O-nSV
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZguXBBlFcDLRiEBBzcxnk4MRe0IJbCARBQ1Fvk-NGutCTbTfawv4E_zUziTQmqgGs8iZJ5jzPzmZCnMocwHrqSpZAcsKRMOSullkzIWKdcS4ipXYPsR3F0nHw4SU_8hlvj2yq3PrFz1KbWuEd-GOEoQyhB4V4tzxmeGoV_V_0RGlfJNQ6RBlu68tm7rScGWxbCj8vFGT_00jlY1pU9gNoDio18FI461P7BN0-Wi7q5LPH8s3_yt4A0u0lu-EySTnvR75ArtrpFdrytNvS5B5R-cZv8_LyqsZ8OCCmCe1taOwqJH10uINMEwbG2ZosNyLXWm9bSTinovKIL8ARUo16sqAdgbSi4SDvHbQg6x9kSP8G1eUmn9AIWmvYjMVRVhv6wrWLKg5_cIcezt9_eHDF_CAPTQkYtMy5MDDfCyUzn0tlEKRWXCSQy2F9hQLipgzDvQDgmtSIrZSJDzbm0HdRfHt8lkwoYvktoHnPhYmlQa5JU5XnpRJm5yJTacWVEQOKtLArtEcrxoIxF0f12y6BS6VlboAQLL8GAsOGuZY_Q8Q_61yjmgRbxtbsL9eq08OZacON4pEoVG_jiPBW5zTVO3cKr69AmLiCPUEmKflh18BLFNIMyP8rCJAvIk44CMTYqbOI5VeumKd5_-v4fRF-_jIieeSJXAzu08oMT8E2I3TWi3BtRgqfQo-VdVOktV5riwqbgzq2aX778eFjGh2JjXmXrNdJA_p0JKCICcq-3ioGzkMpCcp_JgGQjexmxfrxSzc86iHMJmSzUDvf__loPyPUIp1Gw_1TskUm7Wtt9yBHb8mHnCH4BKANqiQ
  priority: 102
  providerName: ProQuest
Title Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/35522679
https://www.proquest.com/docview/2686209048
https://www.proquest.com/docview/2661076774
https://pubmed.ncbi.nlm.nih.gov/PMC9075650
https://doaj.org/article/1df12aba3dfe48568e8c7134eccc0e4f
http://dx.doi.org/10.1371/journal.pone.0268288
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF616YULorzqUsKCkICDIz93vUgIpVVCQaJUhaDeLHu9WyIZO8SORC78Af40M_bGYBQEBy4-eGejeF47Y898Q8hjEcEx7ujUDiE4sIM0dO1USGEz4cvQlQLO1KZA9oydzoI3l-HlDtnMbDUMrLamdjhParbMR1-_rF-Cwb9opjZwd7NptCgLNYKcApKIaJfswdnEcabB26D7rgDWzZhpoPvTzt4B1eD4d956sMjLalso-ntF5S9H1PQGuW5iSzpulWGf7KjiJtk31lvRpwZi-tkt8v18WWKFHRBShPtWtNQUQkG6yCH2BFHadWnna5B0Kde1oo2a0HlBc_ANVKKmLKmBZK0oOE01xxcTdI7dJqana_2cjulPoGjaNsnQpMjoZ1UndmLgUG6T2XTy4eTUNmMZbMmEV9uZdoLMzZgWXEZCqyBJEj8NILTBiosMxB1qOPg185wsVIynIhCOdF2hGvC_yL9DBgUw_IDQyHeZ9kWGehSESRSlmqVce1kqtZtkzCL-RhaxNJjlODojj5sPcRxyl5a1MUowNhK0iN3tWrSYHX-hP0Yxd7SIuN3cKJdXsTHg2M206yVp4mfwxFHIIhVJ7MOFvy4dFWiLPEAlidv21c5vxGMOib_HnYBb5FFDgagbBZb1XCWrqopfv_v4D0TvL3pETwyRLoEdMjGtFPBMiObVozzqUYLvkL3lA1TpDVeq2MOGIUeAW4edGzXfvvywW8YfxVK9QpUrpIGInDNIKyxyt7WKjrMQ3EK4z4VFeM9eeqzvrxTzTw3ouYDYFrKJw_8hq3vkmoddLFi3yo7IoF6u1H2ILet0SHb5JYdrdOLidfpqSPaOJ2fnF8Pmbc2wcSd4_Tb5AQ1ahIU
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKcoALorwaKNQgEHBIm6cTIyG0PJZdWgqCFvUWHMcuKy3JsskK7W_gv_AbmUmclKAKuPS6nmSd8fibmWTmMyH3eQxu3NGpHUJwYAdp6Nopl9xm3JehKzn41LpAdp-ND4M3R-HRGvnZ9sJgWWWLiTVQZ4XEd-Q7HrYyOBwM7tn8m42nRuHX1fYIjcYsdtXqO6Rs5dPJS1jfB543enXwYmybUwVsybhX2Zl2gszNmOaRjLlWgRDCTwPwzFgwkMFsQw1-S8O_ZaFiUcoD7kjX5armrot9uO85cj7wwZNjZ_rodYv8gB2MmfY8P3J3jDVsz4tcbUOuA8lN3HN_9SkBnS8YzGdFeVqg-2e95m8OcHSZXDKRKx02prZO1lR-hawbbCjpI0Ng_fgq-fF-UWD9HghSJBNXtNAUAk06n0FkC4ZiV4U9W4EdFXJVKVobIZ3mdAbIQyXa4YIawteSAiSrKb72oFPsZTEdY6sndEhPaKhp04JDRZ7Rr6oStjBkK9fI4Zksz3UyyEHhG4TGvsu0zzO00iAUcZxqlkbay1KpXZExi_jtWiTSMKLjwRyzpP7MF0Fm1Kg2wRVMzApaxO6umjeMIP-Qf47L3Mkin3f9Q7E4Tgw8JG6mXU-kws_gieOQxSqW2OULU5eOCrRFttBIkqY5tkOlZBg5HkSgThBZ5F4tgZweORYNHYtlWSaTd5_-Q-jjh57QQyOkC1CHFKZRA54JucJ6kps9SUAm2RveQJNutVImJ3sYrmzN_PThu90w3hQLAXNVLFEG4v2IQdJikRvNrug0C6EzJBMRt0jU2y891fdH8umXmlKdQ-QMucrNv09ri1wYH7zdS_Ym-7u3yEUPO2Gw9pVtkkG1WKrbEJ9W6Z0aFCj5fNYo9Asb9aYR
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELbKIiEuiPLXQKEGgYBD2vw6NhJCS0vVpahU0KLeguPYZaUlWTZZoX0G3oinYybxpgRVwKXX9STrjMffzCQznwl5LDi4cc9kbgzBgRtlse9mQgmXiVDFvhLgU5sC2QO2dxy9PYlPVsjPZS8MllUuMbEB6rxU-I58K8BWBk8gzayxZRGHO7uvpt9cPEEKv7Quj9NoTWRfL75D-la9HO3AWj8Jgt03R9t7rj1hwFVMBLWbGy_K_ZwZkSgujI6klGEWgZfG4oEcZh4b8GEG_jmPNUsyEQlP-b7QDY8dD-G-l8jlJEw47jG-3ZWXAI4wZlv1wsTfspaxOS0LvQl5DyQ6vOcKmxMDOr8wmE7K6ryg98_azd-c4e51cs1GsXTYmt0qWdHFDbJqcaKizyyZ9fOb5MfhrMRaPhCkSCyuaWkoBJ10OoEoF4zGrUt3sgCbKtWi1rQxSDou6ARQiCq0yRm15K8VBXjWY3wFQsfY12K7xxYv6JCeUVLTth2HyiKnX3UtXWmJV26R4wtZnttkUIDC1wjloc9MKHK02CiWnGeGZYkJ8kwZX-bMIeFyLVJl2dHxkI5J2nzySyBLalWb4gqmdgUd4nZXTVt2kH_Iv8Zl7mSR27v5oZydphYqUj83fiAzGebwxDxmXHOFHb8wdeXpyDhkA40kbRtlO4RKh4kXQDTqRYlDHjUSyO9R4E45lfOqSkfvP_2H0McPPaGnVsiUoA4lbdMGPBPyhvUk13uSgFKqN7yGJr3USpWe7We4cmnm5w8_7IbxplgUWOhyjjIQ-ycMEhiH3Gl3RadZCKMhsUiEQ5Lefumpvj9SjL809OoComjIW-7-fVob5ArgT_pudLB_j1wNsCkGy2DZOhnUs7m-D6FqnT1oMIGSzxcNQr8AQB6qEg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+the+platelet-to-lymphocyte+ratio+in+lung+cancer+patients+receiving+immunotherapy%3A+A+systematic+review+and+meta-analysis&rft.jtitle=PloS+one&rft.au=Haoyu+Wang&rft.au=Cui+Li&rft.au=Ruiyuan+Yang&rft.au=Jing+Jin&rft.date=2022-05-06&rft.pub=Public+Library+of+Science+%28PLoS%29&rft.eissn=1932-6203&rft.volume=17&rft.issue=5&rft.spage=e0268288&rft_id=info:doi/10.1371%2Fjournal.pone.0268288&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_1df12aba3dfe48568e8c7134eccc0e4f
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon